Precigen (NASDAQ:PGEN) Shares Gap Up After Better-Than-Expected Earnings

Posted by Francis Steltz on Aug 5th, 2026

Precigen, Inc. (NASDAQ:PGEN – Get Free Report)’s stock price gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $6.53, but opened at $7.02. Precigen shares last traded at $7.12, with a volume of 5,214,938 shares traded.

The biotechnology company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.06. The business had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The business’s quarterly revenue was up 6322.7% compared to the same quarter last year.

Key Precigen News

Here are the key news stories impacting Precigen this week:

Positive Sentiment: Strong Q2 results: Precigen reported earnings of $0.05 per share, versus analyst expectations for a loss of approximately $0.01–$0.02, while revenue surged to $54.98 million from $23.25 million a year earlier and exceeded estimates near $28 million. The company also reported $20.1 million in net income attributable to common shareholders. Precigen Q2 Earnings and Revenues Surpass Estimates
Positive Sentiment: PAPZIMEOS commercial momentum: PAPZIMEOS generated $53.1 million in second-quarter net revenue, more than double the prior quarter. Patient-hub enrollment exceeded 500 patients, suggesting expanding adoption, while management said revenue and available funds are expected to support cash-flow break-even by year-end 2026. FDA-granted seven-year market exclusivity also improves the product’s competitive protection. Precigen Reports Second Quarter 2026 Financial Results
Positive Sentiment: Analyst support: HC Wainwright reiterated its Buy rating and maintained a $14 price target, well above recent trading levels. The firm’s endorsement may strengthen investor confidence after the earnings beat. HC Wainwright Reiterates Buy Rating for Precigen
Neutral Sentiment: Unusual options activity: Investors purchased 27,256 call options, roughly 790% above average daily call volume. This signals heightened speculative interest and potentially bullish positioning, but options activity does not guarantee sustained buying in the shares. Precigen Target of Unusually Large Options Trading
Negative Sentiment: Insider selling: COO Rutul Shah sold 33,772 shares for approximately $219,518 under a pre-arranged Rule 10b5-1 plan. Broader reported insider activity shows sales and no purchases over the past six months, which may weigh on sentiment, although planned transactions are not necessarily discretionary bearish signals. Precigen COO Insider Sale

Analysts Set New Price Targets

Several equities analysts have recently issued reports on PGEN shares. Citizens Jmp lifted their price objective on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 14th. HC Wainwright increased their target price on shares of Precigen from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday. Citigroup restated an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Wall Street Zen lowered shares of Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $14.50.

View Our Latest Analysis on PGEN

Insider Activity

In other Precigen news, insider Donald P. Lehr sold 29,131 shares of Precigen stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $4.36, for a total transaction of $127,011.16. Following the transaction, the insider directly owned 755,461 shares in the company, valued at approximately $3,293,809.96. The trade was a 3.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Harry Jr. Thomasian sold 100,000 shares of the business’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $6.06, for a total transaction of $606,000.00. Following the sale, the chief financial officer directly owned 254,535 shares in the company, valued at approximately $1,542,482.10. This trade represents a 28.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 956,500 shares of company stock worth $5,248,371 in the last quarter. Insiders own 41.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. State of Wyoming acquired a new position in Precigen during the first quarter valued at $27,000. NBC Securities Inc. acquired a new stake in Precigen during the 4th quarter worth about $38,000. Caitong International Asset Management Co. Ltd purchased a new position in Precigen during the 3rd quarter valued at about $39,000. Royal Bank of Canada grew its stake in Precigen by 102.6% during the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 5,426 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Precigen in the 3rd quarter valued at about $41,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Stock Up 9.0%

The business has a fifty day moving average price of $5.07 and a two-hundred day moving average price of $4.44. The company has a current ratio of 4.82, a quick ratio of 4.12 and a debt-to-equity ratio of 4.62. The company has a market cap of $2.54 billion, a price-to-earnings ratio of -6.03 and a beta of 1.02.

About Precigen

(Get Free Report)

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.